Alcon
To see an up-to date selection of historical analyses and insights on
Alcon,
visit our
new, dynamically updated Company Summary report pages for Alcon.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Alcon are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Alcon,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Alcon |
1 |
Patanol |
olopatadine |
Anti-histamine |
369 |
425 |
|
15% |
|
|
|
2 |
Travatan |
travoprost |
Prostaglandin F2 analogue |
325 |
424 |
|
31% |
|
|
|
3 |
TobraDex |
tobramycin & dexamethasone |
Aminoglycoside & corticosteroid |
264 |
285 |
|
8% |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Alcon |
- |
Moxifloxacin & Dexamethasone |
Sensory Organs |
Eye preparations |
Quinolone & corticosteroid |
Phase III |
|
|
- |
Arxxant |
Sensory Organs |
Eye preparations |
Protein kinase C (PKC) inhibitor |
Filed |
|
|
- |
Alcon/Shire Ophthalmology Research Project |
Sensory Organs |
Eye preparations |
Eye preparation |
Research project |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Alcon |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
| Market Capitalisation |
24,990 |
24,990 |
| PE Ratio (diluted) - Normalised (x) |
22.9 |
19.2 |
|
|
| Valuing the Enterprise |
| Enterprise Value |
23,271 |
23,271 |
| Free Cash Flow (Pre-Dividends) |
1,059 |
1,213 |
| FCF Yield (%) |
4.6% |
5.2% |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
4,369 |
4,897 |
| Cost of Goods Sold |
(1,075) |
(1,196) |
| S,G & A |
(1,349) |
(1,518) |
| R&D |
(422) |
(512) |
| Other Income/ Expense - Net |
(81) |
(52) |
| EBIT - Normalised |
1,441 |
1,619 |
| Net Interest & Financial Items |
11 |
24 |
| Pre-tax Profits - Normalised |
1,452 |
1,643 |
| Exceptionals |
(249) |
(26) |
| Income Before Taxes |
1,203 |
1,617 |
| Tax |
(272) |
(269) |
| Tax Rate (%) |
22.6% |
16.6% |
| Net Income - Reported |
931 |
1,348 |
| Net Income - Normalised |
1,139 |
1,343 |
|
|
| Per Share Data |
| EPS - Diluted |
2.98 |
4.37 |
| EPS - Basic |
3.04 |
4.43 |
| EPS - Normalised (diluted) |
3.65 |
4.35 |
| EPS - Normalised (basic) |
3.72 |
4.41 |
| Avg. Shares Outstanding - Diluted |
311.9 |
308.7 |
| Avg. Shares Outstanding - Basic |
306.0 |
304.3 |
| DPS |
0.99 |
1.38 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| FDA Approves Alcon's AcrySof(R) IQ ReSTOR(R) +3.0 D Intraocular Lens
|
(Alcon)
|
23-Dec-2008 |
| Akorn, Inc. Announces FDA Approval of Ciprofloxacin HCI Ophthalmic Solution USP, 0.3%
|
(Akorn)
|
12-Dec-2008 |
| Alcon Announces AZARGA(R) Ophthalmic Suspension Approved for Treatment of Patients with Glaucoma or Ocular Hypertension in the European Union
|
(Alcon)
|
02-Dec-2008 |
| Alcon Launches New AcrySof(R) ReSTOR(R) Intraocular Lens for Presbyopia Outside the U.S.
|
(Alcon)
|
15-Sep-2008 |
| Alcon Expands Refractive Surgery Options with the Introduction of the AcrySof(R) Phakic Intraocular Lens Outside the U.S.
|
(Alcon)
|
12-Sep-2008 |
| Alcon Expands Refractive Surgery Options with the Introduction of the AcrySof(R) Phakic Intraocular Lens Outside the U.S.
|
(Alcon)
|
12-Sep-2008 |
| Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration
|
(Alcon)
|
11-Jul-2008 |
| Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
|
(Alcon)
|
15-Apr-2008 |
| Alcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma
|
(Alcon)
|
06-Mar-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Alcon |
AL-37807 |
- |
|
|
AL-43546 |
- |
|
|
Alcon/Shire Ophthalmology Research Project |
- |
|
|
Alomide |
lodoxamide tromethamine |
|
|
Anecortave acetate |
anecortave acetate |
|
|
Ariflo |
cilomilast |
|
|
Arxxant |
ruboxistaurin |
|
|
Atropine |
atropine |
|
|
Azarga |
brinzolamide & timolol |
|
|
Azopt |
brinzolamide |
|
|
Betaxon |
levobetaxolol |
|
|
Betoptic |
betaxolol |
|
|
Betoptic S |
betaxolol |
|
|
Brimonidine tartrate |
brimonidine tartrate |
|
|
BSS Plus |
glutathione |
|
|
Carteolol |
carteolol |
|
|
Ciloxan |
ciprofloxacin |
|
|
Cipro HC |
ciprofloxacin & hydrocortisone |
|
|
CiproDex |
ciprofloxacin & dexamethasone |
|
|
Ciprofloxacin |
ciprofloxacin |
|
|
Cromolyn |
cromolyn sodium |
|
|
Cyclogyl |
cyclopentolate hydrochloride |
|
|
Dipivefrin |
dipivefrin |
|
|
Emadine |
emedastine |
|
|
Extravan/DuoTrav |
travoprost & timolol |
|
|
Fluorescite |
fluorescein sodium |
|
|
Fluorometholone |
fluorometholone |
|
|
Gentamicin |
gentamicin |
|
|
Glaucoma agents |
- |
|
|
Glauconex |
befunolol |
|
|
Iopidine |
apraclonidine |
|
|
Levobunolol |
levobunolol |
|
|
Maxitrol |
neomycin, polymyxin & dexamethasone |
|
|
Metipranolol |
metipranolol |
|
|
Moxifloxacin & Dexamethasone |
moxifloxacin & dexamethasone |
|
|
Neomycin, Polymyxin & Hydrocortisone |
neomycin, polymyxin & hydrocortisone |
|
|
Neoretna |
- |
|
|
Nevanac |
nepafenac |
|
|
NovaBay programme |
- |
|
|
Ofloxacin |
ofloxacin |
|
|
Opthalmic disease project |
- |
|
|
Optrin |
motexafin lutetium |
|
|
Origenis Research Project |
- |
|
|
Patanase |
olopatadine |
|
|
Patanol |
olopatadine |
|
|
Phenylephrine |
phenylephrine |
|
|
Pilocarpine |
pilocarpine |
|
|
Pred Acetate |
prednisolone |
|
|
Procalyx |
icomucret |
|
|
Proparacaine |
proparacaine |
|
|
Retaane |
anecortave acetate |
|
|
Systane |
polyethylene glycol 400, propylene glycol, HP-Guar & borate |
|
|
Timolol GFS |
timolol maleate |
|
|
TobraDex |
tobramycin & dexamethasone |
|
|
TobraDex ST |
tobramycin & dexamethasone |
|
|
Tobramycin |
tobramycin |
|
|
Tobrex |
tobramycin |
|
|
Travatan |
travoprost |
|
|
Triesence |
triamcinolone acetonide |
|
|
Trifluridine |
trifluridine |
|
|
Trimethoprim & Polymyxin |
trimethoprim & polymyxin |
|
|
Tropicamide |
tropicamide |
|
|
Vexol |
rimexolone |
|
|
Vigamox |
moxifloxacin |
|
|
Vismed |
sodium hyaluronate |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
